Blog Single

Executive Summary: Electronic health record (EHR) and health IT software companies are valued differently from traditional service businesses because a meaningful share of their worth comes from recurring revenue quality, retention, and the difficulty customers face when switching systems. Buyers and investors typically focus on annual recurring revenue (ARR), net revenue retention (NRR), implementation stickiness, and the switching cost moat to determine whether a company deserves a premium valuation multiple. For Chicago business owners in this sector, understanding how these drivers affect discounted cash flow (DCF) outcomes, ARR multiples, and precedent transaction data is essential before pursuing a sale, recapitalization, or financing.

Introduction

EHR and health IT businesses sit at the intersection of software economics and healthcare operations. Their products often become deeply embedded in a provider’s daily workflow, from clinical documentation and billing to scheduling, analytics, and compliance. That embedded nature changes how valuation analysts and buyers assess risk, growth, and durability of cash flow.

Unlike a one-time software license or a project-based health IT consulting firm, a subscription-based EHR platform can support high recurring revenue and strong visibility into future performance. The question is not only how much revenue the company generates today, but how sticky that revenue is, how much it expands within the existing customer base, and how costly it would be for a hospital, physician group, or specialty practice to move to another platform.

For owners in Chicago, including companies serving the medical corridors around the Illinois Medical District, River North, or the broader Chicagoland provider community, these valuation questions have practical consequences. The difference between a 4x and 10x revenue multiple can materially change a transaction outcome, as well as the tax planning needed under Illinois and federal rules.

Why This Metric Matters to Investors and Buyers

Investors and strategic buyers do not pay premium multiples simply because a company sells software. They pay for predictability, retention, and expansion potential. In EHR and health IT, those characteristics are often reflected in ARR and NRR.

ARR signals revenue visibility

Annual recurring revenue shows the contracted or highly predictable portion of revenue expected over the next 12 months. In valuation, ARR is often more important than reported revenue when a business has subscription contracts, maintenance fees, or recurring SaaS subscriptions layered onto implementation services. A company with $10 million of ARR and low churn may command a meaningfully higher valuation than a business with the same total revenue but less recurring visibility.

Buyers prefer ARR because it reduces forecasting uncertainty. In a DCF model, more visible recurring revenue lowers the perceived risk of future cash flows, which can reduce the discount rate assumption and support a higher present value. If recurring revenue is growing 20 percent or more and gross retention remains strong, buyers generally assign stronger multiples than they would to slower-growing software assets.

NRR measures expansion and customer health

Net revenue retention captures how much recurring revenue remains from a customer cohort after churn, downgrades, upgrades, and cross-sells are considered. In practical terms, NRR answers a critical question, does the existing customer base become more valuable over time?

For high-quality SaaS and health IT businesses, NRR above 110 percent is often viewed positively, while 120 percent or higher can signal a strong expansion engine. When NRR is at or above 100 percent, the business is growing even before new customer acquisition is counted. That creates a powerful effect in valuation, because the company is not just replacing lost revenue, it is compounding it.

In EHR software, NRR may be driven by new modules, analytics, revenue cycle tools, patient engagement, interoperability features, or compliance enhancements. Buyers often pay a premium where expansion revenue is recurring and tied to long-term customer relationships rather than one-off projects.

Implementation stickiness lowers churn risk

Implementation stickiness refers to how deeply a software product becomes integrated into the customer’s clinical, financial, and operational workflows. EHR systems are notoriously difficult to implement, train, and customize. Once installed, they often touch scheduling, charting, coding, payments, reporting, and regulatory workflows. That complexity makes switching expensive and disruptive.

From a valuation standpoint, implementation stickiness suggests lower churn, longer customer life, and stronger cash flow durability. Buyers value the time, labor, data migration effort, retraining cost, and operational risk associated with switching platforms. In healthcare, those costs can be significant enough to create a defensible moat.

The switching cost moat justifies premium multiples

The switching cost moat is one of the most important features supporting a higher valuation in health IT. If a customer would face substantial financial, technical, and clinical disruption by changing systems, the incumbent vendor enjoys pricing power and lower revenue volatility.

This moat matters because transaction multiples are ultimately a shorthand for risk-adjusted future cash flow. A software company with moderate growth but extremely sticky revenue may be worth more than a less sticky business with similar top-line growth. Buyers are not just buying current sales, they are buying a recurring stream of future earnings with a reduced probability of loss.

Key Valuation Methodology and Calculations

Several valuation approaches are relevant for EHR and health IT software companies, with DCF, ARR multiples, EBITDA multiples, and precedent transactions usually carrying the most weight.

ARR multiples in software valuation

ARR multiples are often the starting point for subscription software companies. For lower-growth or less differentiated platforms, market multiples may fall in a more conservative range. Stronger SaaS businesses with robust retention, high gross margins, and consistent growth can trade at substantially higher multiples.

For EHR and health IT companies, the multiple depends on several factors, including growth rate, NRR, customer concentration, profitability, implementation economics, and regulatory risk. A company with 15 to 25 percent growth, 110 percent plus NRR, and low churn may receive a premium to a peer with flat growth and weak expansion revenue. If the software is mission-critical and embedded in provider operations, the market may view it as more durable than a general-purpose software tool.

EBITDA multiples remain relevant

Even in software, EBITDA matters, particularly for mature businesses or those with heavy services revenue. Buyers often examine adjusted EBITDA multiples to test whether the company is generating quality cash earnings after normalizing owner compensation, implementation expenses, and non-recurring items.

A business with recurring revenue and strong operating leverage may support a higher EBITDA multiple because incremental revenue is profitable and less dependent on expensive customer acquisition. Conversely, if implementation revenue is low margin and sales cycles are long, the EBITDA multiple may compress despite a healthy ARR base.

DCF analysis connects economics to present value

DCF valuation is especially useful when a software company has clear revenue cohorts, recurring renewals, and visible expansion assumptions. The analyst projects revenue by segment, estimates churn, implementation service conversion, renewal rates, and attach rates for new modules, then applies an appropriate discount rate to the resulting free cash flow.

In a health IT business, small changes in churn assumptions can materially affect value. If gross churn moves from 4 percent to 8 percent annually, the long-term ARR base may decline much faster than expected. Similarly, NRR moving from 115 percent to 95 percent can shift a model from expansion mode to replacement mode, which lowers enterprise value materially. Buyers will scrutinize those assumptions closely.

Precedent transactions and market comps

Precedent transactions help anchor valuation to what buyers have actually paid for similar assets. In EHR and health IT, deals are typically priced based on a blend of ARR, EBITDA, and strategic fit. A company with a defensible niche, such as ambulatory specialty workflows or compliance-heavy vertical software, may command more than a broader but less sticky platform.

Strategic buyers often pay more than financial buyers if the target fills a product gap, expands customer access, or creates cross-sell opportunities. That strategic premium is especially relevant in Chicagoland, where healthcare technology, provider services, and investor interest intersect across the metro area.

Chicago Market Context

Chicago has a deep healthcare ecosystem, with major hospitals, physician groups, payers, and technology talent concentrated across the metropolitan area. That creates a supportive market for EHR and health IT vendors serving specialty practices, outpatient groups, revenue cycle functions, and digital health workflows.

For business owners in the Loop or River North, proximity to financial sponsors, law firms, and healthcare advisors can improve deal visibility and transaction readiness. Buyers in Chicago often expect a clear story around ARR quality, customer concentration, and implementation economics before moving forward with due diligence. They also pay close attention to Illinois tax implications and Cook County operating realities where relevant, particularly when a business has a mix of software, services, and physical operations.

Local deal activity also tends to reward companies that can demonstrate resilience. A provider facing labor shortages, reimbursement pressure, and administrative complexity is more likely to value software that reduces friction and improves workflow. That dynamic supports strong demand for EHR and health IT products with measurable ROI, especially in sectors tied to the Chicago financial services industry, healthcare delivery, and regulated service businesses.

Common Mistakes or Misconceptions

One common mistake is assuming all recurring revenue is equal. A contract book with high churn, poor implementation outcomes, or heavy customer concentration should not be valued like a diversified SaaS platform with low attrition.

Another misconception is focusing only on revenue growth while ignoring retention quality. Growth driven by aggressive discounting or expensive customer acquisition may appear attractive, but if NRR is weak, value creation is limited. Buyers will discount that growth if the revenue base is unstable.

Owners also sometimes overstate the strength of their switching cost moat. True stickiness is not just long contract terms. It is the combination of workflow integration, data migration complexity, training burden, compliance risk, and operational disruption. If a client can switch vendors in a few weeks with little pain, the moat is not as wide as the seller may think.

Finally, some sellers underestimate the effect of services revenue. Implementation, customization, and support can be valuable, but if those revenues are not scalable, they may pull down the overall multiple. Buyers prefer a model where implementation is necessary but the core recurring software revenue drives enterprise value.

Conclusion

EHR and health IT software valuations are driven by more than headline revenue. ARR, NRR, implementation stickiness, and switching costs all influence how buyers assess risk and reward. When those metrics are strong, businesses can justify premium multiples because they offer durable cash flows, expansion potential, and meaningful barriers to customer churn. When those metrics are weak, even a growing software company may trade at a discount.

For Chicago business owners, the right valuation approach should combine market evidence, financial modeling, and practical insight into customer retention and implementation economics. Chicago Business Valuations works with owners, investors, accountants, and advisors to deliver confidential, well-supported valuations tailored to transaction, tax, and strategic planning needs. If you are considering a sale, recapitalization, partner buyout, or financing event, schedule a confidential valuation consultation with Chicago Business Valuations.